LENSAR Q2 2025: ALLY System placements up 107%, procedure volumes increase 23% YoY.

• LENSAR reports Q2 2025 results • 18 ALLY robotic cataract laser systems placed in Q2 2025 • Additional 18 ALLY systems pending installation as of June 30, 2025 • ALLY installed base grew 107% YoY • Total installed base grew 23% over Q2 2024 • Worldwide procedure volumes increased 23% over Q2 2024 • Company focused on advanced robotic laser solutions for cataracts treatment

LENSAR Inc. (LNSR), a leading provider of innovative femtosecond laser systems for refractive cataract surgery, has reported its second quarter 2025 financial results. The company demonstrated significant growth in its ALLY Robotic Cataract Laser System placements and installations, reflecting a strong market demand for advanced robotic laser solutions.

During Q2 2025, LENSAR placed 18 ALLY robotic cataract laser systems, with an additional 18 systems pending installation as of June 30, 2025. This performance marks a 107% year-over-year (YoY) increase in the installed base of ALLY systems. The company's total installed base grew by 23% over the same period in Q2 2024, indicating robust expansion in its market footprint.

Worldwide procedure volumes also increased by 23% over Q2 2024, underscoring the company's growing influence in the global ophthalmic care market. LENSAR's focus on advanced robotic laser solutions for cataract treatment continues to drive market penetration and operational efficiency.

Despite these positive indicators, LENSAR reported a net loss of $27.3 million for the quarter, largely attributed to warrant liability changes following a 58% stock price increase. The company anticipates accelerating revenue growth in 2025, with Q1 2025 growth projected at 27% and further acceleration in subsequent quarters. LENSAR expects to achieve positive Adjusted EBITDA in 2025, signaling a potential turnaround in financial performance.

LENSAR's recent announcements, including the proposed merger with Alcon Research, LLC, further highlight its strategic focus on expanding its market presence and technological leadership in the femtosecond laser-assisted cataract surgery (FLACS) segment. The merger, valued at up to $430 million, aims to strengthen Alcon's FLACS portfolio and expand advanced laser technology globally.

References:
[1] https://www.stocktitan.net/news/LNSR/
[2] https://www.stocktitan.net/news/LNSR/